Vraylar vs Trintellix
A side-by-side look at two mental health medications advertised on TV. Informational only — not medical advice.
| US Vraylar | US Trintellix | |
|---|---|---|
| Generic name | cariprazine | vortioxetine |
| Drug class | Atypical Antipsychotic | Serotonin Modulator (Antidepressant) |
| Treats | Bipolar disorder, schizophrenia, depression (add-on) | Major depressive disorder |
| Category | Mental Health | Mental Health |
| Manufacturer | AbbVie | Takeda/Lundbeck |
| Year approved | 2015 | 2013 |
| FDA warning | Black box warning | Black box warning |
| Est. TV ad spend | $200M | $130M |
| Common side effects | Movement disorders, Drowsiness, Restlessness, Weight changes | Nausea, Sexual problems, Constipation, Vomiting |
Trintellix
Frequently asked questions
Is Vraylar or Trintellix better?
Neither is universally "better." Vraylar (cariprazine) and Trintellix (vortioxetine) are both used for mental health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Vraylar and Trintellix?
Vraylar is a Atypical Antipsychotic made by AbbVie, while Trintellix is a Serotonin Modulator (Antidepressant) made by Takeda/Lundbeck. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Vraylar has the larger estimated TV advertising budget of the two.